Camonsertib — Investigational Agent
Other · Phase 1/2 · Repare Therapeutics / Roche
Mechanism of Action
Camonsertib is a potent, orally bioavailable, selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, a master regulator of the replication-stress response. In tumors harboring specific DNA damage response (DDR) alterations (e.g., ATM, BRCA1/2, RAD51C, CDK12), ATR inhibition abrogates cell-cycle checkpoint control and forces mitotic entry with unrepaired DNA, producing synthetic-lethal cell death. Camonsertib was engineered for high potency at low doses to widen its therapeutic index and enable tolerable combinations. It shows activity as monotherapy in molecularly…
Investigational Indications
- DDR-mutant ovarian cancer
- BRCA/ATM-mutant breast cancer
- PARP-inhibitor-resistant tumors
- Molecularly selected solid tumors (prostate, pancreatic)